Insilico Medicine has successfully debuted on the Hong Kong Stock Exchange (HKEX), raising a total of HKD 2.277 billion (USD 293 million) in what stands as the largest biotech IPO on the Hong Kong market this year. The company's share price opened at HKD 35, a 45.53% premium to its issue price of HKD 24.05, following exceptionally strong pre-market demand. The listing marks Insilico as the first AI-driven biopharmaceutical company to list under the Main Board's Rule 8.05, garnering significant attention from global investors.

The offering was heavily oversubscribed, with the Hong Kong public offering portion receiving approximately 1,427 times more orders than shares available, locking in over HKD 328 billion. The international placement was 26 times oversubscribed. A consortium of 15 cornerstone investors, including Eli Lilly and Tencent, participated in the deal, signalling strong cross-industry and institutional confidence in AI-driven drug discovery. Insilico, which leverages its proprietary Pharma.AI platform, plans to allocate the IPO proceeds primarily to advancing its clinical-stage pipeline, early-stage discovery and further development of its automated laboratory infrastructure.

According to PharmCube's MedAlpha® database, a total of 30 Chinese drug developers debuted in the stock market this year. Click here to request a free trial for MedAlpha®.